Examkin

Soru

Zorluk: OrtaGynecologic Infections

A 24-year-old nulliparous woman presents to the gynecology clinic reporting new-onset lower abdominal pain and increased vaginal discharge for the past 3 days. One week ago, she visited a different clinic for a routine wellness examination, during which an endocervical swab was collected for sexually transmitted infection screening. She has not received any treatment since that visit. Her temperature is 38.0°C (100.4°F), blood pressure is 112/74 mm Hg, and pulse is 88/min. Physical examination reveals mild diffuse lower abdominal tenderness. Pelvic examination shows mucopurulent cervical discharge, cervical motion tenderness, and bilateral adnexal tenderness. No adnexal masses are palpable. A point-of-care urine pregnancy test is negative. She is able to tolerate oral intake without nausea. The results of the endocervical nucleic acid amplification test (NAAT) from her visit last week are available in the electronic medical record: the test is positive for Chlamydia trachomatis and negative for Neisseria gonorrhoeae. She has no known drug allergies. Which of the following is the most appropriate next step in pharmacotherapy for this patient?

  1. Administration of single-dose intramuscular ceftriaxone, plus oral doxycycline and oral metronidazole for 14 daysCevap
  2. B
    Administration of oral doxycycline and oral metronidazole for 14 days
  3. C
    Administration of oral doxycycline for 7 days
  4. D
    Administration of single-dose intramuscular ceftriaxone and a single dose of oral azithromycin
  5. E
    Admission to the hospital for intravenous piperacillin-tazobactam

Cevap

The correct answer is the administration of single-dose intramuscular ceftriaxone, plus oral doxycycline and oral metronidazole for 14 days.
This patient meets the clinical criteria for acute Pelvic Inflammatory Disease (PID). According to the CDC guidelines, empiric outpatient treatment for PID must include a single intramuscular dose of ceftriaxone, 14 days of oral doxycycline, and 14 days of oral metronidazole. Crucially, this comprehensive empiric regimen must be administered even if recent endocervical screening tests are negative for Neisseria gonorrhoeae or Chlamydia trachomatis. The upper genital tract flora in PID is polymicrobial, and treatment should not be narrowed strictly based on lower-tract NAAT results.

Adım Adım Çözüm

1
Identify the clinical syndrome based on presenting signs and symptoms.
The patient has fever, lower abdominal pain, cervical motion tenderness, and adnexal tenderness, which establishes the clinical diagnosis of acute Pelvic Inflammatory Disease (PID).
Recognizing the transition from lower genital tract colonization to upper genital tract infection is critical for determining the intensity and duration of therapy.
2
Determine the appropriate treatment setting (inpatient vs. outpatient).
Outpatient management is indicated.
The patient is not pregnant, has no signs of a surgical emergency, lacks a tubo-ovarian abscess, and is able to tolerate oral intake.
3
Select the guideline-concordant empiric antibiotic regimen for outpatient PID in the context of known NAAT results.
The regimen must include ceftriaxone, doxycycline, and metronidazole.
Empiric PID treatment must cover N. gonorrhoeae, C. trachomatis, and anaerobes. Even if a lower-tract (endocervical) test is negative for N. gonorrhoeae, ceftriaxone must still be administered because the upper genital tract infection is polymicrobial and may harbor organisms missed by lower-tract screening.

Anahtar Kavram

Outpatient management of Pelvic Inflammatory Disease (PID) requires a 14-day empiric regimen covering C. trachomatis, N. gonorrhoeae, and anaerobes (Ceftriaxone IM x1 + Doxycycline PO x14 days + Metronidazole PO x14 days), regardless of negative lower-tract screening results for specific pathogens.
Bu soruyu puanla

Konular

Gynecologic Infections

Bu konudan daha fazla soru